retatrutide clinical trials obesity New GLP-1 drug, retatrutide, shows added benefits TRIUMPH-3 🇦🇺 retatrutide cardiovascular/obesity clinical

Forest plot depicting the meta-analysis of odds ratios (ORs) for inadequate bowel preparation in glucagon-like peptide-1 receptor agonists users vs

home Home About Us Newsroom Proposed Colorado bill looks to regulate compounded GLP-1 medications A bill sponsor said the legislation is designed to regulate the ingredients used for transparency and safety

When documenting adverse effects of Mounjaro, clinicians should first code the manifestation (the clinical presentation or symptom) followed by an external cause code from the Y40-Y59 range to indicate that the manifestation was caused by a medication in therapeutic use

Semaglutide uses much lower doses (0.25mg to 2.4mg), requiring different concentrations

I feel like Im just getting started

In April 2025 Pfizer was forced to discontinue a clinical trial with one of its experimental GLP-1 medicines to treat obesity due to potential drug induced liver injury found in one of the participants